Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04548518
Other study ID # Tri Fluvac Vaccine in Elderly
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 3, 2020
Est. completion date December 31, 2023

Study information

Verified date August 2022
Source Mahidol University
Contact Punnee Pitisuttithum
Phone (662) 6435599
Email punnee.pit@mahidol.ac.th
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is aim to evaluate the Immunogenicity with two groups of participants who will received a seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or an active comparator (licensed influenza vaccine).


Description:

This is a phase III, non-inferiority double-blinded, randomized, controlled trial of immunogenicity with two groups of participants who will received a seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or an active comparator (licensed influenza vaccine). A total of about 816 healthy Thai male and female adult volunteers ≥ 65 years of age; 408 participants will be randomized to receive the GPO Tri Fluvac and 408 will receive an active comparator (a 1:1 ratio).


Recruitment information / eligibility

Status Recruiting
Enrollment 816
Est. completion date December 31, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Age = 65 years old on the day of screening, having Thai ID card or equivalent - Able to read and write in Thai and sign written informed consent form - Able to attend all scheduled visits and to comply with all trial procedures. - Healthy or medically stable, as established by medical history and physical examination. For individuals with medical conditions, symptoms/signs, if present must be stable, under control or unchanged for the past three months. If medication is used to treat the condition, the medication dose must have been stable for at least one month preceding vaccination. Exclusion Criteria: - Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study. - Hypersensitivity after previous administration of any vaccine. - Having a history of H1N1, H3N2 or FluB infection within 3 months preceding enrollment to the trial - Vaccination against influenza in the past 6 months preceding enrollment to the trial - Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 28 visit. - History of bronchial asthma, chronic lung diseases, chronic rhinitis - History of immunodeficiency state - History of immunosuppression < 6 months prior to immunization - History of anaphylactic or other allergic reactions to influenza vaccine or any vaccine component or excipient (e.g. egg proteins, gentamicin or thimerosal) - History of Guillain-Barré Syndrome or cerebrovascular events - Having acute infection with fever > 38 degree Celsius or noninfectious diseases (within 72 hours) preceding enrollment in the trial - Volunteers who have been taking immunoglobulin products or have had a blood transfusion during past 3 months before the beginning of the trial or planned receipt of such products prior to the Day 28 visit. - Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures - Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled, or could interfere with the evaluation of the vaccine - Study site employees who are involved in the protocol and/or may have direct access to study related area

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GPO Tri Fluvac vaccine
Each dose of Tri Fluvac contains a total of 45 micrograms (µg) hemagglutinin (HA) per 0.5 ml dose (15 µg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (= 5.75 µg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (= 1.0µg), formaldehyde (= 100µg), tween 80 (= 0.9µg), triton x-100 (=0.05µg) and gentamicin (=0.075µg).
Licensed influenza vaccine
The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020

Locations

Country Name City State
Thailand Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University Bangkok

Sponsors (2)

Lead Sponsor Collaborator
Mahidol University The Government Pharmaceutical Organization

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and percentage of seroconverted participants at 28 days post vaccination seroconversion is defined as a serum HI antibody titer meeting the following four fold rising criteria:
Pre-vaccination titer <1:10 and a post-vaccination measured on Day 28 of =1:40; or
Pre-vaccination titer =1:10 and at least a four-fold increase in post-vaccination measured on Day 28.
28 days
Primary Geometric Mean Titers (GMTs) of serum HI antibodies at baseline (Day 0) and post- vaccination (Day 28). Geometric mean titers (GMTs) of serum HI antibodies pre- (Day 0) and post-vaccination (Day 28) for each of the three vaccine antigens. GMTs will be calculated with 95% CI. 28 days
Secondary Number and percentage of participants with solicited local and systemic adverse events. post vaccination Solicited local adverse events including redness/erythema, swelling/induration, pain, and limitation of arm movement. Solicited systemic adverse events including fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, and headache. 30 minutes, Day 1-3 post-vaccination
Secondary Number and percentage of participants with unsolicited adverse event. Number and percentage of participants with unsolicited adverse event occuring during the entire study period (Days 0-180) 180 days
Secondary Number and percentage of participants with serious adverse event. Number and percentage of participants with serious adverse event occuring during the entire study period (Days 0-180) 180 days
Secondary Number and percentage of participants with HI response with and without pre-existing HI antibody. Number and percentage of participants with a HI antibody titer =1:40 (seroprotective level) to each of the three vaccine antigens. 28 days
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A